Nuance Pharma
Privately held: no public share price · China
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
ensifentrine(Ohtuvayre) | Approved | PDE3/PDE4Small molecule | Chronic Obstructive Pulmonary Disease |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
January 2026Filing acceptedensifentrineChina's NMPA accepts Nuance Pharma's NDA for Ohtuvayre (ensifentrine) in COPD
CN, NMPA · Nuance Pharma · Source ↗
Financial reports
No financial reports recorded.